In this module of a Four-Part Expert Interview Series, R. James White, MD, along with Aaron B. Waxman, MD, PhD, course chair, will review advancements in the treatment and management of pulmonary arterial hypertension (PAH). The pipeline of available therapies will be relayed, along with strategies for selecting optimal single/combination therapies for PAH patients. The clinical relevance of recent treatment trials will be analyzed, particularly for the prostacyclin class. Upon completion of this 30-minute module, learners will better understand how to apply recent data of emerging and emerged agents to clinical practice when treating patients with pulmonary arterial hypertension.
Pulmonologists, cardiologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with PAH.
1. Understand the mechanism of action of current available therapies for pulmonary arterial hypertension
2. Identify safety and efficacy data of current and emerging therapies for the treatment of PAH
Aaron B. Waxman, MD, PhD
Pulmonary and Critical Care Medicine
Director, Pulmonary Vascular Disease Program
Executive Director, Center for Pulmonary-Heart Diseases
Brigham and Women’s Hospital Heart and Vascular Center
Associate Professor of Medicine, Harvard Medical School
James White, MD, PhD
Professor, Department of Medicine Pediatrics and Pharmacology and Physiology
University of Rochester
Pulmonary Hypertension Physician
University of Rochester Medical Center
Rochester, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Aaron B. Waxman, MD, PhD||Consultant/Advisor: Acceleron Pharma, Inc.; Medtronic; United Therapeutics Corporation|
|R. James White, MD, PhD||Consultant/Advisor: Bayer AG; Gilead; Merck & Co.; United Therapeutics CorporationResearch/Grant Support: Bayer AG; PhaseBio Pharmaceuticals Inc; United Therapeutics Corporation|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation. AcademicCME’s ANCC provider number is P0491.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 0.50 CNE contact hours (0.50 CNE pharmacotherapeutic contact hours).
This activity has been supported by an independent educational grant from Actelion Pharmaceuticals US, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion Pharmaceuticals US, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].